Analytical Data
-
Gene name
HLA-A*24:02&B2M&MAGE-A3(IMPKAGLLI) Tetramer
- Application
-
Alternative Names
MAGE family member A3; HIP8; HYPD; CT1.3; MAGE3; MAGEA6
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59600.1 (G25-T305)&P61769
-
Expression Region
AAA59600.1 (G25-T305)&P61769 (I21-M119)&IMPKAGLLI
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*24:02, B2M, and the MAGE-A3 (IMPKAGLLI) tetramer recombinant protein is pivotal in the field of cancer immunotherapy and neoantigen research. HLA-A*24:02 is a prevalent human leukocyte antigen (HLA) allele in Asian populations, and it plays a crucial role in presenting antigenic peptides to T cells, thereby initiating an immune response. MAGE-A3 is a cancer/testis antigen, often overexpressed in various tumors, making it an attractive target for anti-tumor immune responses. The specific peptide IMPKAGLLI, derived from MAGE-A3, can bind to HLA-A*24:02, forming a complex that is recognized by cytotoxic T lymphocytes (CTLs). By constructing a tetrameric complex of HLA-A*24:02 and B2M with the MAGE-A3 peptide, researchers can effectively identify and isolate antigen-specific T cells. This tetramer allows for a detailed study of T cell responses in cancer patients, aiding in the understanding of immune tolerance and the potential for developing personalized immunotherapies. Additionally, the tetramer can be used in clinical settings to monitor the efficacy of therapeutic vaccines targeting MAGE-A3, contributing to advancements in personalized cancer treatment strategies.
